22 September 2023
Ondo InsurTech Plc
("Ondo" or "the Company")
Warrant / Exercise of Options / Total Voting Rights Update
Ondo InsurTech Plc ("Ondo"), the London-listed leader in claims prevention technology for home insurers, is pleased to provide an update on its Shares in Issue and Total Voting rights in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
During the first three weeks of September, a total of 448,333 ordinary shares were issued pursuant to warrant exercises and these shares were admitted to trading under the Company's blocklisting arrangement.
In addition, the company announces that options over 47,224 ordinary shares have been exercised.
A separate application has been made to the London Stock Exchange for 47,224 ordinary shares to be admitted to trading on London Stock Exchange. These shares are expected to be admitted to trading at 8am on 27 September 2023. The shares will, when issued, rank pari passu with the existing ordinary shares of the Company.
Following admission, the company will have 80,922,716 ordinary shares in issue. The Company holds no shares in treasury.
Each ordinary share carries the right to one vote in relation to all circumstances at general meetings of the Company. The total number of voting rights in the Company is therefore 80,922,716.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquiries
For further information, please visit www.ondoplc.com or contact the following:
Ondo InsurTech Plc | Craig Foster, CEO | +44 (0) 800 783 9866 |
SI Capital Ltd (Company Broker) | Nick Emerson Jon Levinson | +44 (0) 1483 413500 +44 (0) 20 3143 0600 |
Cassiopeia Services Ltd (PR & Investor Relations) | Stefania Barbaglio | +44 (0) 7949 690338
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.